Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 48   

Articles published

ARNA 2.71 +0.06 (2.26%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the Pipeline
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Now Could Be The Time To Speculate On Achillion Pharmaceuticals
That will cost Achillion a large percentage of all future profits (still not an awful deal at this point), just as Arena had to do.
FDA Considers Faster Approval Process for Obesity Drugs
Arena Pharmaceuticals Inc.'s Belviq weight-loss pill and Vivus Inc.'s Qsymia may have been approved earlier for use by morbidly obese people had such a path existed.
Eisai's Epilepsy Drug Reduces Weight in Obese Patients
The efficacy was similar to Roche Holding AG's Xenical and Arena Pharmaceuticals Inc.'s Belviq. Side effects such as mood changes and memory problems occurred more frequently than with a placebo, the authors of the study at Duke University Medical ...
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
Top Angel Investors of New England: An Innovation Slideshow
Investment Philosophy: "Invest in dynamic entrepreneurs in fields I like and understand. I look for some barriers to entry (IP), and if successful the potential for the company to be a large player. I try to stay away from small niche plays." ...
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
TechMan: Thank the Cold War for E-ZPass technology
Pharmaceuticals can be tracked through warehouses, and livestock and pets may have tags injected, allowing positive identification of the animal.
Novartis delays restart of Lincoln production
A quick check of pharmacies in Lincoln showed that the Walgreens at 13th and O streets and CVS at 56th Street and Nebraska 2 both had Excedrin Migraine in stock, while National Pharmacy at 33rd and A streets and Hy-Vee at 50th and O streets did not ...
IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry
... prostate cancer; Onyx Pharmaceuticals (NASDAQ:ONXX) for Kyprolis that treats a rare blood cancer; VIVUS Inc. (NASDAQ:VVUS) for Qsymia (TM) for the treatment of obesity; Arena Pharmaceuticals (NASDAQ:ARNA) for Lorcaserin that also treats obesity; ...